Latest Atricure (ATRC) Headlines
Zacks Rank #5 Additions for Friday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Friday
AtriCure to Present at the Cowen and Company 34th Annual Health Care Conference
Business Wire - Fri Feb 28, 3:01PM CST
AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, today announced that it will present at the Cowen and Company 34th Annual Health Care Conference at the Boston Marriott Copley Place on Wednesday, March 5, 2014. Management is scheduled to present at 9:20 a.m. Eastern Time.
AtriCure Reports Fourth Quarter and Full Year 2013 Financial Results
Business Wire - Thu Feb 27, 3:01PM CST
--2013 U.S. sales of $62.3 million - up 18.4%
AtriCure Prices Public Offering of Common Stock
Business Wire - Thu Feb 13, 8:02AM CST
AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, today announced the pricing of its previously announced underwritten public offering of 4,250,000 shares of its common stock at a public offering price of $19.25 per share. AtriCure is offering 3,023,025 shares and selling stockholders are offering 1,226,975 shares of common stock. In connection with the offering, AtriCure has also granted the underwriter a 30-day option to purchase up to an additional 637,500 shares of common stock to cover over-allotments, if any.
AtriCure Announces Commencement of Public Offering of Common Stock
Business Wire - Wed Feb 12, 3:01PM CST
AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, today announced that AtriCure and certain selling stockholders intend to offer shares of AtriCure common stock in a public offering. AtriCure also expects to grant the underwriters a 30-day option to purchase additional shares of its common stock to cover over-allotments, if any. AtriCure plans to use the net proceeds from the offering for general corporate purposes and working capital. AtriCure will not receive any proceeds from the sale of common stock by the selling stockholders.
Concise Analysis of the International Cardiac Prosthetic Devices Market - Forecasts to 2019
M2 - Mon Feb 10, 5:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/r3r5p5/cardiac) has announced the addition of the "Concise Analysis of the International Cardiac Prosthetic Devices Market - Forecasts to 2019" report to their offering. Sometimes pathological diseases such as diabetes, obesity, hypertension and others might hamper the working mechanism of the valves. Hence, cardiac prosthetics are designed to replace the diseased or damaged natural valves. Artificial valves mainly are of two types namely mechanical heart valves and biological heart valves. Mechanical valves are made up of synthetic materials such as polymers, ceramics and metals. Biologic or the tissue valves are made up of materials from biological origin after modification using physico-chemical treatments. Cardiac diseases are the most common cause of deaths and more people die due to cardiac diseases compared to any other form of disease. According to WHO projection, number of people who will die due to cardiac disease will reach 23.3 million by 2030. Hence, with the rise in number of cardiac diseases the demand for cardiac prosthetic devices is poised to grow at an impressive rate. Mechanical valves dominate the total cardiac devices market followed by tissue valves. Mechanical valves are preferred over tissue valve as they are made from biocompatible material and are durable with long term flexibility. However, patient implanted with mechanical valves need a long term anticoagulation therapy and is not preferred for elderly patients or hemolytic patients. But, tissue valves are expected to show a significant growth in near future owing to technological advancements such as introduction of suture-less valves and transcatheter valves. Currently tissue valves have limited life span and might undergo structural changes due to calcification. North America accounts for the largest overall market with approximately 2.5% of the total population suffering from valve related diseases. Key Topics Covered: 1 Preface 2 Executive Summary 3 Market Overview 4 Cardiac Prosthetic Devices Market, by Segments 5 Cardiac Prosthetic Devices Market, by Geography 6 Recommendations 7 Company Profiles Companies Mentioned: - Abbott Laboratories - Abiomed, Inc - AtriCure, Inc - Boston Scientific Corporation - Edward Lifesciences Corporation - Medtronic, Inc - Siemens Healthcare - Sorin Group - St Jude Medical, Inc For more information visit http://www.researchandmarkets.com/research/r3r5p5/cardiac
AtriCure to Announce Fourth Quarter and Full Year 2013 Financial Results
Business Wire - Tue Feb 04, 3:20PM CST
AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, will release its financial results for the fourth quarter and full year 2013 on Thursday, February 27, 2014.
Infonetics: Exploding Mobile Device Traffic, Acquisitions Heat Up Diameter Signaling Controller Market
Business Wire - Fri Jan 31, 1:02AM CST
Market research firm Infonetics Research released excerpts from its just-published market size and forecast report on Diameter signaling controllers, which handle and secure the exponentially increasing Diameter signaling traffic on service provider networks triggered by mobile devices and machines.
Silver Stream Acquires 5,000 Metres of Solomon Pillars Gold Property Diamond Drill Core
Marketwire Canada - Thu Jan 30, 2:36PM CST
Silver Stream Mining Corp. (the "Company" or "Silver Stream") (OTCQB:AGSM) and Sage Gold Inc. ("Sage Gold") (TSX VENTURE:SGX), a Canadian public company listed on the TSX Venture Exchange, announced today that approximately 5,000 metres of Solomon Pillars Gold Property ("Property") historic drill core stored in Copper Cliff, Ontario has been acquired.
AtriCure to Present at the Leerink Swann 2014 Global Healthcare Conference
Business Wire - Mon Jan 20, 3:01PM CST
AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, today announced that it will present at the Leerink Swann 2014 Global Healthcare Conference at the Waldorf Astoria Hotel in New York on Wednesday, February 12, 2014. Management is scheduled to present at 11:30 a.m. Eastern Time.
Stock Price Movements, Completion of Acquisitions, and Clinical Trial Initiations - Research Report on Endocyte, PharMerica, Synta, AtriCure, and Cytokinetics
PR Newswire - Wed Jan 15, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
Why AtriCure, Inc. Shares Surged
Sean Williams, The Motley Fool - Motley Fool - Fri Jan 10, 2:55PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of AtriCure , a developer of cardiac surgical...
Nasdaq stocks posting largest percentage increases
AP - Fri Jan 10, 12:30PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Upgrade Alert for AtriCure (ATRC)
Comtex SmarTrend(R) - Fri Jan 10, 7:58AM CST
AtriCure (NASDAQ:ATRC) was upgraded from Market Perform to Outperform at JMP Securities today. The stock closed yesterday at $19.01 on volume of 115,000 shares, above average daily volume of 102,000. In the past 52 weeks, shares of AtriCure have traded between a low of $7.25 and a high of $19.20 and closed yesterday at $19.01, which is 162% above that low price. In the last five trading sessions, the 50-day moving average (MA) has climbed 3.1% while the 200-day MA has risen 1.9%.
AtriCure Announces Preliminary Results for Fourth Quarter and Full Year 2013 and Issues 2014 Guidance
Business Wire - Thu Jan 09, 3:00PM CST
AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, today announced preliminary financial results for fourth quarter and full year 2013 and issued 2014 financial guidance.
AtriCure Up 87.0% Since SmarTrend Uptrend Call (ATRC)
Comtex SmarTrend(R) - Thu Jan 09, 10:56AM CST
SmarTrend identified an Uptrend for AtriCure (NASDAQ:ATRC) on September 13th, 2013 at $10.06. In approximately 4 months, AtriCure has returned 86.98% as of today's recent price of $18.81.
82.7% Return Seen to Date on SmarTrend AtriCure Call (ATRC)
Comtex SmarTrend(R) - Thu Jan 02, 9:32AM CST
SmarTrend identified an Uptrend for AtriCure (NASDAQ:ATRC) on September 13th, 2013 at $10.06. In approximately 4 months, AtriCure has returned 82.66% as of today's recent price of $18.38.
AtriCure Completes Acquisition of Estech
Business Wire - Thu Jan 02, 8:00AM CST
AtriCure, Inc. (Nasdaq: ATRC), a leading Atrial Fibrillation medical device provider, today announced the completion of the previously announced acquisition of Endoscopic Technologies, Inc. d/b/a Estech ("Estech"). Estech develops and markets a portfolio of innovative surgical ablation devices that enable physicians to perform a variety of traditional and minimally invasive procedures using Estech's proprietary temperature controlled RF energy.
Uptrend Call Working As AtriCure Stock Rises 87.9% (ATRC)
Comtex SmarTrend(R) - Thu Dec 26, 9:04AM CST
SmarTrend identified an Uptrend for AtriCure (NASDAQ:ATRC) on September 13th, 2013 at $10.06. In approximately 3 months, AtriCure has returned 87.87% as of today's recent price of $18.90.
Global Atrial Fibrillation Market Report 2013 - 2019
M2 - Mon Dec 23, 3:42AM CST
Research and Markets (http://www.researchandmarkets.com/research/686s6l/atrial) has announced the addition of the "Global Atrial Fibrillation Market Report 2013 - 2019" report to their offering. Atrial fibrillation is a type of cardiac arrhythmia identified by an abnormal cardiac rhythm caused by a disturbance in the heart's electrical system. Atrial fibrillation (AF) is one of the most commonly occurring cardiac rhythm conditions. As a potentially life-threatening disease and a condition that's expensive to treat, the healthcare system views treatment for this condition as a strategically critical area to address. This report analyzes the market for atrial fibrillation from the point of view of various pharmacological and non-pharmacological treatment products. The pharmacological AF treatment market has been further classified into the specific drugs commonly used for treating AF, namely anti-arrythmics and anti-coagulants. The non-pharmacological atrial fibrillation devices market has been further sub-divided into therapeutic procedures such as catheter ablation procedures, maze surgery and electric cardioversion. The major methods of catheter ablation procedures studied in this report include radiofrequency, high intensity focused ultrasound (HIFU), cryoablation, microwave ablation and laser catheter ablation. Key Topics Covered: 1 Preface 1.1 Report description 1.2 Market segmentation 1.3 Research methodology 2 Executive Summary 3 Market Overview 3.1 Introduction 3.2 Market Dynamics 3.3 Porter's Five Forces Analysis for the Global Atrial Fibrillation Market 4 Atrial Fibrillation Market, by Treatment Types 4.1 Overview 4.2 Global Pharmacological Treatments for Atrial Fibrillation Market 4.3 Non-Pharmacological Treatment for Atrial Fibrillation Market 5 Atrial Fibrillation Market, by Geography 5.1 Overview 5.2 North America 5.3 Europe 5.4 Asia-Pacific 5.5 Rest of the World (RoW) 6 Competitive Landscape 7 Recommendations 7.1 Investing in emerging markets, particularly China and Brazil 7.2 Focus on emerging technologies such as mini-maze procedure and catheter ablation 8 Company Profiles Companies Mentioned: - AtriCure, Inc - Biosense Webster, Inc - Boehringer Ingelheim GmbH - Boston Scientific Corporation - Bristol-Myers Squibb Corporation - CardioFocus, Inc - Endoscopic Technologies, Inc - Johnson and Johnson Ltd - Sanofi Aventis - St Jude Medical, Inc For more information visit http://www.researchandmarkets.com/research/686s6l/atrial
Zacks Rank #5 Additions for Friday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Friday
AtriCure to Present at the Cowen and Company 34th Annual Health Care Conference
Business Wire - Fri Feb 28, 3:01PM CST
AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, today announced that it will present at the Cowen and Company 34th Annual Health Care Conference at the Boston Marriott Copley Place on Wednesday, March 5, 2014. Management is scheduled to present at 9:20 a.m. Eastern Time.
AtriCure Reports Fourth Quarter and Full Year 2013 Financial Results
Business Wire - Thu Feb 27, 3:01PM CST
--2013 U.S. sales of $62.3 million - up 18.4%
AtriCure Prices Public Offering of Common Stock
Business Wire - Thu Feb 13, 8:02AM CST
AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, today announced the pricing of its previously announced underwritten public offering of 4,250,000 shares of its common stock at a public offering price of $19.25 per share. AtriCure is offering 3,023,025 shares and selling stockholders are offering 1,226,975 shares of common stock. In connection with the offering, AtriCure has also granted the underwriter a 30-day option to purchase up to an additional 637,500 shares of common stock to cover over-allotments, if any.
AtriCure Announces Commencement of Public Offering of Common Stock
Business Wire - Wed Feb 12, 3:01PM CST
AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, today announced that AtriCure and certain selling stockholders intend to offer shares of AtriCure common stock in a public offering. AtriCure also expects to grant the underwriters a 30-day option to purchase additional shares of its common stock to cover over-allotments, if any. AtriCure plans to use the net proceeds from the offering for general corporate purposes and working capital. AtriCure will not receive any proceeds from the sale of common stock by the selling stockholders.
Concise Analysis of the International Cardiac Prosthetic Devices Market - Forecasts to 2019
M2 - Mon Feb 10, 5:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/r3r5p5/cardiac) has announced the addition of the "Concise Analysis of the International Cardiac Prosthetic Devices Market - Forecasts to 2019" report to their offering. Sometimes pathological diseases such as diabetes, obesity, hypertension and others might hamper the working mechanism of the valves. Hence, cardiac prosthetics are designed to replace the diseased or damaged natural valves. Artificial valves mainly are of two types namely mechanical heart valves and biological heart valves. Mechanical valves are made up of synthetic materials such as polymers, ceramics and metals. Biologic or the tissue valves are made up of materials from biological origin after modification using physico-chemical treatments. Cardiac diseases are the most common cause of deaths and more people die due to cardiac diseases compared to any other form of disease. According to WHO projection, number of people who will die due to cardiac disease will reach 23.3 million by 2030. Hence, with the rise in number of cardiac diseases the demand for cardiac prosthetic devices is poised to grow at an impressive rate. Mechanical valves dominate the total cardiac devices market followed by tissue valves. Mechanical valves are preferred over tissue valve as they are made from biocompatible material and are durable with long term flexibility. However, patient implanted with mechanical valves need a long term anticoagulation therapy and is not preferred for elderly patients or hemolytic patients. But, tissue valves are expected to show a significant growth in near future owing to technological advancements such as introduction of suture-less valves and transcatheter valves. Currently tissue valves have limited life span and might undergo structural changes due to calcification. North America accounts for the largest overall market with approximately 2.5% of the total population suffering from valve related diseases. Key Topics Covered: 1 Preface 2 Executive Summary 3 Market Overview 4 Cardiac Prosthetic Devices Market, by Segments 5 Cardiac Prosthetic Devices Market, by Geography 6 Recommendations 7 Company Profiles Companies Mentioned: - Abbott Laboratories - Abiomed, Inc - AtriCure, Inc - Boston Scientific Corporation - Edward Lifesciences Corporation - Medtronic, Inc - Siemens Healthcare - Sorin Group - St Jude Medical, Inc For more information visit http://www.researchandmarkets.com/research/r3r5p5/cardiac
AtriCure to Announce Fourth Quarter and Full Year 2013 Financial Results
Business Wire - Tue Feb 04, 3:20PM CST
AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, will release its financial results for the fourth quarter and full year 2013 on Thursday, February 27, 2014.
Infonetics: Exploding Mobile Device Traffic, Acquisitions Heat Up Diameter Signaling Controller Market
Business Wire - Fri Jan 31, 1:02AM CST
Market research firm Infonetics Research released excerpts from its just-published market size and forecast report on Diameter signaling controllers, which handle and secure the exponentially increasing Diameter signaling traffic on service provider networks triggered by mobile devices and machines.
Silver Stream Acquires 5,000 Metres of Solomon Pillars Gold Property Diamond Drill Core
Marketwire Canada - Thu Jan 30, 2:36PM CST
Silver Stream Mining Corp. (the "Company" or "Silver Stream") (OTCQB:AGSM) and Sage Gold Inc. ("Sage Gold") (TSX VENTURE:SGX), a Canadian public company listed on the TSX Venture Exchange, announced today that approximately 5,000 metres of Solomon Pillars Gold Property ("Property") historic drill core stored in Copper Cliff, Ontario has been acquired.
AtriCure to Present at the Leerink Swann 2014 Global Healthcare Conference
Business Wire - Mon Jan 20, 3:01PM CST
AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, today announced that it will present at the Leerink Swann 2014 Global Healthcare Conference at the Waldorf Astoria Hotel in New York on Wednesday, February 12, 2014. Management is scheduled to present at 11:30 a.m. Eastern Time.
Stock Price Movements, Completion of Acquisitions, and Clinical Trial Initiations - Research Report on Endocyte, PharMerica, Synta, AtriCure, and Cytokinetics
PR Newswire - Wed Jan 15, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
Why AtriCure, Inc. Shares Surged
Sean Williams, The Motley Fool - Motley Fool - Fri Jan 10, 2:55PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of AtriCure , a developer of cardiac surgical...
Nasdaq stocks posting largest percentage increases
AP - Fri Jan 10, 12:30PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Upgrade Alert for AtriCure (ATRC)
Comtex SmarTrend(R) - Fri Jan 10, 7:58AM CST
AtriCure (NASDAQ:ATRC) was upgraded from Market Perform to Outperform at JMP Securities today. The stock closed yesterday at $19.01 on volume of 115,000 shares, above average daily volume of 102,000. In the past 52 weeks, shares of AtriCure have traded between a low of $7.25 and a high of $19.20 and closed yesterday at $19.01, which is 162% above that low price. In the last five trading sessions, the 50-day moving average (MA) has climbed 3.1% while the 200-day MA has risen 1.9%.
AtriCure Announces Preliminary Results for Fourth Quarter and Full Year 2013 and Issues 2014 Guidance
Business Wire - Thu Jan 09, 3:00PM CST
AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, today announced preliminary financial results for fourth quarter and full year 2013 and issued 2014 financial guidance.
AtriCure Up 87.0% Since SmarTrend Uptrend Call (ATRC)
Comtex SmarTrend(R) - Thu Jan 09, 10:56AM CST
SmarTrend identified an Uptrend for AtriCure (NASDAQ:ATRC) on September 13th, 2013 at $10.06. In approximately 4 months, AtriCure has returned 86.98% as of today's recent price of $18.81.
82.7% Return Seen to Date on SmarTrend AtriCure Call (ATRC)
Comtex SmarTrend(R) - Thu Jan 02, 9:32AM CST
SmarTrend identified an Uptrend for AtriCure (NASDAQ:ATRC) on September 13th, 2013 at $10.06. In approximately 4 months, AtriCure has returned 82.66% as of today's recent price of $18.38.
AtriCure Completes Acquisition of Estech
Business Wire - Thu Jan 02, 8:00AM CST
AtriCure, Inc. (Nasdaq: ATRC), a leading Atrial Fibrillation medical device provider, today announced the completion of the previously announced acquisition of Endoscopic Technologies, Inc. d/b/a Estech ("Estech"). Estech develops and markets a portfolio of innovative surgical ablation devices that enable physicians to perform a variety of traditional and minimally invasive procedures using Estech's proprietary temperature controlled RF energy.
Uptrend Call Working As AtriCure Stock Rises 87.9% (ATRC)
Comtex SmarTrend(R) - Thu Dec 26, 9:04AM CST
SmarTrend identified an Uptrend for AtriCure (NASDAQ:ATRC) on September 13th, 2013 at $10.06. In approximately 3 months, AtriCure has returned 87.87% as of today's recent price of $18.90.
Global Atrial Fibrillation Market Report 2013 - 2019
M2 - Mon Dec 23, 3:42AM CST
Research and Markets (http://www.researchandmarkets.com/research/686s6l/atrial) has announced the addition of the "Global Atrial Fibrillation Market Report 2013 - 2019" report to their offering. Atrial fibrillation is a type of cardiac arrhythmia identified by an abnormal cardiac rhythm caused by a disturbance in the heart's electrical system. Atrial fibrillation (AF) is one of the most commonly occurring cardiac rhythm conditions. As a potentially life-threatening disease and a condition that's expensive to treat, the healthcare system views treatment for this condition as a strategically critical area to address. This report analyzes the market for atrial fibrillation from the point of view of various pharmacological and non-pharmacological treatment products. The pharmacological AF treatment market has been further classified into the specific drugs commonly used for treating AF, namely anti-arrythmics and anti-coagulants. The non-pharmacological atrial fibrillation devices market has been further sub-divided into therapeutic procedures such as catheter ablation procedures, maze surgery and electric cardioversion. The major methods of catheter ablation procedures studied in this report include radiofrequency, high intensity focused ultrasound (HIFU), cryoablation, microwave ablation and laser catheter ablation. Key Topics Covered: 1 Preface 1.1 Report description 1.2 Market segmentation 1.3 Research methodology 2 Executive Summary 3 Market Overview 3.1 Introduction 3.2 Market Dynamics 3.3 Porter's Five Forces Analysis for the Global Atrial Fibrillation Market 4 Atrial Fibrillation Market, by Treatment Types 4.1 Overview 4.2 Global Pharmacological Treatments for Atrial Fibrillation Market 4.3 Non-Pharmacological Treatment for Atrial Fibrillation Market 5 Atrial Fibrillation Market, by Geography 5.1 Overview 5.2 North America 5.3 Europe 5.4 Asia-Pacific 5.5 Rest of the World (RoW) 6 Competitive Landscape 7 Recommendations 7.1 Investing in emerging markets, particularly China and Brazil 7.2 Focus on emerging technologies such as mini-maze procedure and catheter ablation 8 Company Profiles Companies Mentioned: - AtriCure, Inc - Biosense Webster, Inc - Boehringer Ingelheim GmbH - Boston Scientific Corporation - Bristol-Myers Squibb Corporation - CardioFocus, Inc - Endoscopic Technologies, Inc - Johnson and Johnson Ltd - Sanofi Aventis - St Jude Medical, Inc For more information visit http://www.researchandmarkets.com/research/686s6l/atrial
